Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced that it has retained Makovsky + Company, a leading global, independent public relations, investor relations and branding firm headquartered in New York City, for the development of a strategic communications and investor relations program.

David Bupp, Neoprobe’s President and CEO, said, “Makovsky + Company’s experience in working with emerging health and small cap companies was a determining factor in our decision to retain the firm. Our company is at an important stage in its history. We expect to hit a number of significant milestones in the near future including the commercialization of Lymphoseek and the commencement of the RIGS clinical development program, making it imperative that we have a strong strategic and investor communications program in place. Makovsky will help guide our communications strategy and generate increased investor awareness for our company among key audiences regarding the exciting Neoprobe business initiatives.”

In addition to Mr. Bupp, the strategic communications and investor relations program will be overseen by Brent Larson, Neoprobe’s Vice President and Chief Financial Officer.

Gil Bashe, Makovsky Executive Vice President, said “Naturally, we are excited about the opportunity to represent Neoprobe, given the important developments that lie ahead for the company. We look forward to working with Neoprobe’s strong management team in implementing a new communications program for the company.”

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe ® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek ® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

About Makovsky + Company

Founded in 1979, Makovsky + Company ( www.makovsky.com) is one of the nation’s leading independent global public relations, investor relations and branding consultancies, focused in financial services, professional services, health care, technology, energy and branding and interactive. The firm attributes its success to its original vision: that the Power of Specialized Thinking™ is the best way to build reputation, sales and fair valuation for a client. Based in New York City, the firm has agency partners in more than 25 countries and in 35 U.S. cities through IPREX ( www.IPREX.com), the second largest worldwide public relations agency partnership, of which Makovsky is a founder.

Copyright Business Wire 2010